Table 1.
Lipid metabolism alterations in EGFR TKI-resistant NSCLC models.
| Lipid Metabolism Alteration | EGFR-TKI | Overcoming Resistance | Refs |
|---|---|---|---|
| FASN-mediated palmitoylation of mutant EGFR | Gefitinib | Orlistat treatment | [48] |
| Elevated levels of SREBP1 and/or FASN | Osimertinib | Genetic knockdown of SREBP1 | [49] |
| FASN overexpression | Gefitinib/ Osimertinib | G28 treatment | [94] |
| Constitutive activation of SREBP1 | Gefitinib | Fatostatin treatment | [50] |
| High LD content and SCD1 expression | Gefitinib | Inhibition of LDs formation by g-PPT | [62] |
| FAO upregulation | Osimertinib | Etomoxir treatment | [67] |
| LDLR expression upregulation | Gefitinib | Atorvastatin treatment | [83] |
| Undefined | Gefitinib | Simvastatin treatment | [119] |